ADVANTAGES AND PROSPECTS OF TARGETED THERAPY IN ONCOLOGICAL PRACTICE: A LITERATURE REVIEW

A. Murina, А. Uaisova, A. Ergalieva

2022

Closed access Metadata (CSL-JSON)
DOI 10.52532/2521-6414-2022-1-63-70-80
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Relevance: Cancer is the second leading cause of death globally and is expected to be responsible for approximately 19.3 million new cases and 10 million deaths in 2022. With an unprecedented understanding of the molecular pathways that drive the development and progression of human cancers, novel targeted therapies have become an exciting new development for anticancer medicine. These targeted therapies, also known as biologic therapies, have become a primary treatment modality by blocking the growth of cancer cells by specifically targeting molecules required for cell growth and tumorigenesis. However, due to their specificity, these new therapies are expected to have better efficacy and limited adverse side effects than other treatment options, including hormonal and chemotherapy. The study aimed to present an overview of the advantages and prospects of targeted therapy in oncological practice. Methods: The search was carried out in the following databases: Scopus, Medline, Cochrane, PubMed, and Science Direct for 2016- 2021. Sources were searched for the following keywords: clinical trials, immunotherapy, monoclonal antibodies, small molecular weight inhibitors, and targeted therapy. Results: This review explores the clinical development, successes, and challenges facing targeted anticancer therapies, including small molecule inhibitors and antibody-targeted therapies. The authors describe targeted therapies to epidermal growth factor receptor, vascular endothelial growth factor, human epidermal growth factor receptor 2, anaplastic lymphoma kinase, BRAF, T-cell mediated immune response inhibitors, cytotoxic T-lymphocyte-associated protein 4, and programmed cell death protein-1/PD-1 ligand. Conclusion: Over the past decade, there have been significant changes in cancer treatment, including targeted therapy, which has become more common. However, targeted drugs show low activity in monotherapy. In addition, the selection of patients for targeted therapy remains a difficult task since there are not enough reliable biomarkers to predict the action of most targeted agents. Therefore, it requires a deeper study of molecular biology, namely signaling pathways that determine the pathogenesis of cancers.